William Blair Analysts Lower Earnings Estimates for Danaher

Danaher Co. (NYSE:DHR) – Equities research analysts at William Blair reduced their Q3 2025 earnings per share (EPS) estimates for Danaher in a report issued on Monday, January 13th. William Blair analyst M. Larew now forecasts that the conglomerate will post earnings per share of $1.92 for the quarter, down from their previous forecast of $1.97. The consensus estimate for Danaher’s current full-year earnings is $7.49 per share.

DHR has been the subject of a number of other research reports. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a report on Thursday, October 31st. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Evercore ISI boosted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Scotiabank began coverage on shares of Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Finally, Citigroup decreased their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $286.80.

Danaher Price Performance

Shares of DHR opened at $241.94 on Thursday. The company has a market capitalization of $174.75 billion, a P/E ratio of 46.17, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. Danaher has a twelve month low of $222.53 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $235.07 and a 200 day moving average of $253.45.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s revenue was up 3.1% compared to the same quarter last year. During the same period last year, the business earned $2.02 EPS.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Decker Retirement Planning Inc. purchased a new stake in Danaher in the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the third quarter worth approximately $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher in the third quarter worth $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Danaher during the 3rd quarter valued at $55,000. Institutional investors own 79.05% of the company’s stock.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.